LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Lantern Pharma To Advance EMA-Cleared Phase 1B/2 Trial Of Lp-184 (Zirdafulven) In Biomarker-Selected Advanced Bladder Cancer
Brief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments
Brief: Lantern Pharma Confirms Panna Sharma Continues To Serve As President And CEO Alerts Investors To False Third-Party Report
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
Lantern Pharma up after FDA allows trial of pediatric brain cancer drug
Brief: Lantern Pharma And Starlight Therapeutics Announce FDA Clearance Of Ind For A Planned Phase 1 Pediatric Cns Cancer Trial Of Star-001
Brief: Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas
Brief: Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru